Anti-wrinkle agent
Citronellol, indole, or amyl butyrate-based agents inhibit collagen and elastin degrading enzymes, addressing the inadequacies of existing wrinkle treatments by promoting collagen production and reducing wrinkle formation, effectively addressing the aging-related decrease in collagen and elastin.
Patent Information
- Application Number
- PCT/JP2024/016756
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-15
- Filing Date
- 2024-05-01
- Publication Date
- 2024-11-21
AI Technical Summary
Current anti-wrinkle agents are inadequate in effectively addressing the decrease in collagen and elastin production associated with aging, which contributes to wrinkle formation, and there is a need for innovative solutions that target collagen and elastin metabolism.
A wrinkle improving agent containing citronellol, indole, or amyl butyrate as active ingredients, which act as MMP-1 and NEP inhibitors, thereby reducing collagen and elastin degradation and promoting their production, thereby addressing wrinkle formation.
The use of citronellol, indole, or amyl butyrate suppresses the expression of collagen and elastin degrading enzymes, leading to increased collagen production and improved wrinkle reduction, as confirmed by gene expression and protein production measurements.
Smart Images

Figure JPOXMLDOC01-APPB-T000001 
Figure JPOXMLDOC01-APPB-T000002 
Figure JPOXMLDOC01-APPB-T000003
Abstract
Description
Wrinkle improvement agent
[0001] The present invention relates to a wrinkle improving agent containing citronellol, indole, farnesol, or amyl butyrate as an active ingredient.
[0002] Wrinkles are common with aging, and a decrease in collagen and elastin in the dermis is thought to be one of the major causes. Many anti-wrinkle agents have been reported, including nicotinamide (JP 2023-001403 A, etc.) and oyster extract (JP 2022-191664 A).
[0003] Meanwhile, it has recently been discovered that olfactory receptors are expressed in various organs (Non-Patent Document 1), and it has been suggested that olfactory receptors are also expressed in fibroblasts and may be involved in collagen metabolism (Non-Patent Document 2). For example, Patent Document 1 reports that geraniol, a rose fragrance component, has the effect of promoting collagen and elastin production.
[0004] Japanese Patent Application Laid-Open No. 2022-130050
[0005] Pharmaceutics. 2021 Aug 23;13(8):1314Int J Mol Sci. 2021 Aug 27;22(17):9273
[0006] An object of the present invention is to obtain a wrinkle improving agent.
[0007] The present inventors have conducted extensive research focusing on odor components and have discovered that citronellol, farnesol, and amyl butyrate have the effect of improving wrinkles, leading to the present invention.
[0008] The present invention relates to the following: [1] A wrinkle improving agent containing one or more active ingredients selected from citronellol, indole, farnesol, and amyl butyrate. [2] An MMP-1 expression inhibitor containing one or more active ingredients selected from citronellol, indole, farnesol, and amyl butyrate. [3] An NEP expression inhibitor containing one or more active ingredients selected from citronellol, indole, farnesol, and amyl butyrate. [4] A collagen degradation inhibitor containing one or more active ingredients selected from citronellol, indole, farnesol, and amyl butyrate. [5] A collagen increaser containing citronellol as an active ingredient.
[0009] By applying citronellol, indole, farnesol, or amyl butyrate, an anti-wrinkle effect can be expected.
[0010] Indole (CAS number: 120-72-9) is naturally present within the cells of plants and animals and has an animal, rotten, or earthy odor. It is also present in flowers such as gardenia and lilies and is used in perfumes.
[0011] Farnesol (CAS number: 4602-84-0) is a naturally occurring fragrance component found in flowers such as roses and jasmine, and was discovered as a plant fragrance substance and an insect pheromone.
[0012] Amyl butyrate (CAS number: 540-18-1) is a type of ester, has a banana-like aroma, and is an aroma component that is also present in fruits such as apples and strawberries.
[0013] Citronellol (CAS number: 106-22-9) is contained in essential oils such as geranium oil and citronella oil, and is an aromatic component that has a rose-like scent.
[0014] As mentioned above, it has been suggested that olfactory receptors are expressed in fibroblasts and may be involved in collagen metabolism, and it has been reported that geraniol has the effect of promoting collagen and elastin production. Therefore, the present inventors conducted extensive research focusing on odor components and discovered that citronellol, farnesol, and amyl butyrate have the effect of improving wrinkles.
[0015] Therefore, the present invention provides a wrinkle improving agent containing one or more active ingredients selected from citronellol, indole, farnesol, and amyl butyrate.
[0016] Wrinkle improvement can be confirmed, for example, by measuring the reduction in gene expression levels or protein production levels of MMP-1, NEP, etc., in biological samples such as skin fibroblasts, or the suppression or increase in the production levels of proteins involved in wrinkle improvement, such as collagen and elastin. Gene expression levels can be measured using techniques known in the art, such as quantitative PCR or Northern blotting. For example, probes for MMP-1 or NEP mRNA may be used. Protein levels can be measured using techniques known in the art, such as Western blotting, immunostaining, ICM, and ELISA. However, in addition to the above-mentioned methods, wrinkle improvement can also be confirmed by any method, such as visual inspection, measuring the length and number of wrinkles, or measuring specific proteins such as collagen and elastin. For example, the production levels of proteins such as collagen and elastin can be confirmed by measuring the production levels of these proteins in skin samples such as skin models or skin cells such as fibroblasts using ELISA.
[0017] The present invention also provides an agent for promoting MMP-1 gene expression, an agent for suppressing NEP gene expression, an agent for inhibiting collagen degradation, and an agent for increasing collagen, each of which contains one or more active ingredients selected from citronellol, indole, farnesol, and amyl butyrate. In one aspect, these agents act on skin fibroblasts.
[0018] MMP-1 (Matrix Metallopeptidase-1) is a gene that encodes a collagen-degrading enzyme. NEP (Neutral Endopeptidase) is a gene that encodes an elastin-degrading enzyme. Reduced production of MMP-1 preserves collagen in tissues, thereby inhibiting wrinkle formation. Reduced production of NEP also preserves elastin in tissues, thereby inhibiting wrinkle formation.
[0019] Gene expression can be measured by techniques known in the art, such as quantitative PCR, Northern blotting, etc. As described above, suppression of gene expression refers to a decrease that is statistically significant (e.g., a correlated T-test) at a significance level of 5%, and / or a decrease of, for example, 10% or more, 20% or more, 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, 90% or more, or 100%.
[0020] As described above, the amount of protein production can be measured by techniques known in the art, such as Western blotting, immunostaining, ICM, ELISA, etc. In one embodiment, promotion of protein production means an increase with a statistically significant difference (e.g., Student's t-test, Dunnett's test) at a significance level of 5%, and / or an increase of, for example, 1% or more, 2% or more, 3% or more, 4% or more, 5% or more, 10% or more, 20% or more, 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, 90% or more, 100% or more, or more. Suppression of protein production means, for example, a decrease that is statistically significant at a significance level of 5% (e.g., Student's t-test, Dunnett's test), and / or a decrease of, for example, 1% or more, 2% or more, 3% or more, 4% or more, 5% or more, 10% or more, 20% or more, 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, 90% or more, or 100%.
[0021] The collagen degradation inhibitory effect can be measured by measuring the collagen production rate using techniques known in the art, such as ELISA, for example, sandwich ELISA. In one embodiment, the collagen degradation inhibitory effect can be determined when the collagen production rate does not show a statistically significant decrease, for example, at a significance level of 5% (e.g., Student's t-test, Dunnett's test), or when the collagen production rate does not show a decrease of, for example, 1% or more, 2% or more, 3% or more, 4% or more, or 5% or more. Alternatively, the collagen degradation inhibitory effect can be measured by measuring the production amount of genes or proteins involved in collagen degradation. In one embodiment, the collagen degradation inhibitory effect can be determined when MMP-1 shows inhibition of gene expression within the above-mentioned range.
[0022] The collagen-increasing effect can be measured by measuring the collagen production rate by a method known in the art, such as ELISA, for example, sandwich ELISA, etc. In one embodiment, the collagen-increasing effect can be determined to be present when the collagen production rate shows an increase with a statistically significant difference (e.g., Student's t-test, Dunnett's test) at a significance level of 5%, and / or an increase of, for example, 1% or more, 2% or more, 3% or more, 4% or more, 5% or more, 10% or more, 20% or more, 30% or more, 40% or more, 50% or more, or more.
[0023] The biological sample may be a sample in which the wrinkle improvement effect can be measured, or a cell culture in which the expression level of genes such as MMP-1 and NEP, the production level of proteins corresponding to these genes, or the production level of proteins involved in wrinkle improvement such as collagen and elastin can be measured. For example, keratinocytes or fibroblasts, particularly fibroblasts, can be preferably used. Alternatively, a skin sample or a three-dimensionally constructed cultured skin model can be used. The cells may be derived from any animal, but from the perspective of developing cosmetics and pharmaceuticals, cells derived from humans are preferred.
[0024] The present invention also provides a method for improving wrinkles in a subject, comprising applying citronellol, indole, farnesol, or amyl butyrate or the agent of the present invention or a composition containing same.
[0025] Examples of subjects to which the method of the present invention can be applied include subjects who wish to prevent or improve wrinkles, subjects who have been determined to have many or deep wrinkles, subjects who are deficient in collagen or elastin, and subjects who have increased gene expression levels or protein production levels of MMP-1, NEP, etc.
[0026] The method according to the present application is for cosmetic purposes and may exclude medical procedures performed by doctors or medical professionals. The method according to the present application may also be a method for supporting cosmetic procedures of a subject.
[0027] The present invention also provides a composition for improving wrinkles, comprising citronellol, indole, farnesol, or amyl butyrate or the agent of the present invention. The composition may be a cosmetic, a pharmaceutical, or a quasi-drug.
[0028] The composition can be applied via any route, such as transdermal, oral, transmucosal, nasal, intravenous, intraarterial, or subcutaneous, but is preferably applied transdermally, i.e., to the skin, from the viewpoint of acting on the skin. The skin can be applied to any part of the body, such as the face, head, neck, limbs, or trunk.
[0029] In the case of cosmetics, the composition can be incorporated into facial or body cosmetics such as lotions, emulsions, serums, creams, lotions, packs, essences, and gels, makeup cosmetics such as foundations, makeup bases, and concealers, and even bath additives. In the case of transdermal pharmaceuticals, the composition can be formulated into topical skin preparations. The form is not particularly limited as long as it is applicable to the skin, and any dosage form can be applied, for example, a solution, emulsion, solid, semi-solid, powder, powder dispersion, water-oil two-layer separation, water-oil-powder three-layer separation, ointment, gel, aerosol, mousse, stick, etc. In addition, bases and excipients commonly used in cosmetics and topical skin preparations, such as preservatives, emulsifiers, and pH adjusters, may be used.
[0030] The amount of active ingredient in the agent or composition of the present invention can be selected as desired from the viewpoint of exerting the wrinkle-improving effect. For example, citronellol, indole, farnesol, or amyl butyrate can be blended at 0.0005 to 100.0 mM. From the viewpoint of fully exerting the effect, they can be blended preferably at 0.005 mM or more, more preferably at 0.05 mM or more. On the other hand, since citronellol, indole, farnesol, and amyl butyrate have a specific odor, from the viewpoint of avoiding an overly strong odor, they can be blended preferably at 10.0 mM or less, and even more preferably at 5.0 mM or less. The above-mentioned ingredients may be combined in any ratio, and in such cases, it is preferable that the total amount of those ingredients is within the above-mentioned range.
[0031] The present invention also provides citronellol, indole, farnesol, or amyl butyrate for wrinkle reduction, wherein the wrinkle reduction is preferably mediated by suppressing gene expression of MMP-1 and / or NEP. In one aspect, wrinkle reduction is achieved in the dermis by reducing collagen-degrading enzymes and / or elastin-degrading enzymes by suppressing gene expression or protein production of MMP-1 and / or NEP in dermal fibroblasts. In one aspect, wrinkle reduction is achieved in the dermis without a decrease or an increase in collagen production in dermal fibroblasts. In one example of such an aspect, the collagen degradation inhibitory effect of citronellol, indole, farnesol, or amyl butyrate does not result in a decrease in collagen production. In one example of such an aspect, collagen is increased by citronellol, indole, farnesol, or amyl butyrate. In one aspect, the inhibition of collagen degradation is achieved by suppressing gene expression or protein production of MMP-1.
[0032] Furthermore, the present invention also provides the use of citronellol, indole, farnesol, or amyl butyrate in the manufacture of a wrinkle improvement agent.
[0033] All documents mentioned herein are incorporated by reference in their entirety.
[0034] The following examples of the present invention are for illustrative purposes only and do not limit the technical scope of the present invention. The technical scope of the present invention is limited only by the claims. The present invention may be modified, for example, by adding, deleting, or substituting components of the present invention, provided that the modifications do not depart from the spirit of the present invention.
[0035] To confirm the wrinkle-improving effects of citronellol, indole, farnesol, and amyl butyrate, the expression of genes involved in these functions was analyzed. More specifically, the expression levels of MMP-1 and NEP were measured by the method described below.
[0036] Example 1: Effects of citronellol, indole, farnesol, and amyl butyrate on keratinocytes 1-1: Cell culture Human neonatal dermal fibroblast cell line NB1RGB cells (RIKEN BRC, Japan) were cultured in a 24-well plate (Cat No. 3526, Corning, USA) at a density of 10.0 × 10 4 The cells were seeded at a density of 10.0% (v / v) fetal bovine serum (FBS, Cat No. SH30071.03, Hyclone, UK) and 1.0% (v / v) antifungal agent (Antibiotic-Antimycotic 100X, Cat No. 15240-062, Invitrogen, USA) in Dulbecco's Modified Eagle Medium (DMEM, Cat No. 043-30085, Wako, Japan) at a density of 10.0% (v / v) cells / well and cultured for 24 hours in a CO2 incubator (CO2 concentration 5%, 37°C). After removing the medium, the cells were replaced with medium supplemented with indole (CAS number: 120-72-9, Wako Pure Chemical Industries), farnesol (CAS number: 4602-84-0, Wako Pure Chemical Industries), amyl butyrate (CAS number: 540-18-1, Wako Pure Chemical Industries), or citronellol (CAS number: 106-22-9, Wako Pure Chemical Industries) to a final concentration of 0.05 mM, and the cells were further cultured for 48 hours in a CO2 incubator. Medium without these components was used as a control.
[0037] 1-2: RNA extraction and purification, quantification, and purity measurement. RNA was extracted and purified using PureLink™ RNA Mini Kit (Cat No. 12183018A, Invitrogen, USA). A portion of the purified RNA was placed in a UV-transparent 96-well plate and diluted 10-fold with Tris-EDTA buffer. The absorbance at 230 nm, 260 nm, and 280 nm (OD230, OD260, OD280) was measured using a microplate reader (SPARK® 10M TECAN, Switzerland). The RNA concentration was calculated using OD260, and the RNA concentration was adjusted to 10 μg / mL by dilution with TE buffer.
[0038] 1-3: Gene Expression Analysis by Real-Time PCR RNA was reverse-transcribed using SuperScript™ IV VILO™ Master Mix with ezDNase (Cat No. 11766050, Invitrogen, USA). 4 μL of SuperScript™ IV VILO™ Master Mix and 6 μL of nuclease-free water were added per well of an 8-tube array. cDNA was synthesized using a real-time PCR system (QuantStudio™ 3, Applied Biosystems, USA) by heating at 25°C for 10 minutes, 50°C for 10 minutes, and 85°C for 5 minutes. Ten microliters of TaqMan® Fast Advanced Master Mix (Cat No. 4444557, Applied Biosystems, USA), 1 μL of TaqMan Gene Expressor, 7 μL of UltraPure™ Distilled Water (Invitrogen, Cat No. 10977-015, USA), and 2 μL of cDNA were added per well to a PCR plate, and the plate was sealed. Real-time qPCR was performed using an MMP-1 primer (Hs00899658_m1) and an NEP primer (Hs00153510_m1), and a GAPDH primer (Hs02786624_g1) as an internal standard gene, and the threshold cycle (Ct) values of each MMP-1 and NEP gene in each component-supplemented medium were calculated. The Ct values were then corrected using GAPDH to obtain ΔCt values. The gene expression level in the component-supplemented medium was calculated assuming that the gene amount doubled per cycle, with the control gene expression level set to 1. The average value of 3 wells of a 24-well plate was used for gene expression analysis per treatment group.
[0039] The results are shown in Table 1 below.
[0040] As shown in Tables 1 and 2, the addition of indole, farnesol, amyl butyrate, and citronellol to dermal fibroblasts reduced the expression of MMP-1 and NEP.
[0041] Example 2: Effect of citronellol on collagen production In this example, citronellol, which was found to have an inhibitory effect on MMP-1 gene expression in dermal fibroblasts in Example 1, was examined for its effect on collagen production in dermal fibroblasts. 2-1: Cell culture The same NB1RGB cells as in Example 1 were cultured in a 24-well plate (Cat No. 3526, Corning, USA) at 10.0 × 10 4 The cells were seeded at a density of 10.0% (v / v) fetal bovine serum (FBS, Cat No. SH30071.03, Hyclone, UK) and 1.0% (v / v) antifungal agent (Antibiotic-Antimycotic 100X, Cat No. 15240-062, Invitrogen, USA) in Eagle's Minimal Essential Medium (EMEM, Cat No. 051-07615, Wako, Japan) at a density of 10.0% (v / v) cells / well and cultured for 24 hours in a CO2 incubator (CO2 concentration 5%, 37°C). After 24 hours, the medium was removed and replaced with a medium supplemented with citronellol (CAS number: 106-22-9, Wako Pure Chemical Industries, Ltd.) to the final concentrations shown in Table 3 below, and the cells were further cultured for 48 hours in a CO2 incubator. A citronellol-free medium was used as a control.
[0042] 2-2: Evaluation of Cell Activation Effect The effect of citronellol on the proliferation of dermal fibroblasts was evaluated using the following method. The medium was removed from a 96-well plate, which was washed with 100 μL of PBS(-). Then, 100 μL of 0.5 mg / mL 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, CAS No. 298-93-1, Sigma-Aldrich, USA) solution was added, and the plate was incubated for 2 hours in a CO2 incubator. After removing the MTT solution and washing with 100 μL of PBS(-), 200 μL of 2-propanol (CAS No. 67-63-0, Wako, Japan) was added to dissolve the insoluble formazan. After uniformly dispersing the dye in the 96-well plate, the absorbance at 570 nm (OD570) was measured using a microplate reader (SPARK® 10M, TECAN, Switzerland). The OD570 of the control group was set at 100%, and the OD570 of the citronellol-added group, i.e., the effect of cell proliferation, was calculated as the cell activation effect (%) of citronellol. The average value of 3 wells of a 96-well plate was used for each treatment group to analyze the cell activation effect.
[0043] 2-3: Collagen Measurement The supernatant of the culture cultured in 2-1 was dispensed into a new 96-well plate and stored frozen (-80°C). The collagen production rate in this culture supernatant was measured by sandwich ELISA to evaluate the effect of citronellol on collagen quantity. 100 μL of the culture supernatant diluted 4-fold with PBS (-) was added to a high-adsorption 96-well plate and incubated overnight at 4°C. Type I collagen solution (Cat No. 009-001-103, RCK, USA) was used as a standard substance. The solid-phase culture supernatant was removed, and the microplate was washed with 200 μL of PBS(−) containing 0.05% Tween® 20 (PBS-T, Tween® 20: CAS No. 9005-64-5, Sigma-Aldrich, USA). 150 μL of a 1% bovine serum albumin (BSA, Cat No. PRL68700-50G, Proliant, USA) solution was added, and the plate was incubated at 37°C for 1 hour. After removing the BSA solution and washing with 200 μL of PBS-T, 100 μL of a 100 ng / mL biotin-labeled Collagen Type I Antibody (Cat No. 600-406-103, ROCKLAND, USA) solution prepared in 0.5% BSA-containing PBS(-) was added and incubated for 1 hour at 37 ° C. After removing the antibody solution and washing with 200 μL of PBS-T, 100 μL of a Streptavidin-HRP (Cat No. CJ30H-1, Agilent Technologies, USA, 1:10,000) solution prepared in 0.5% BSA-containing PBS(-) was added and incubated for 30 minutes at room temperature. After removing the streptavidin-HRP solution and washing with 200 μL of PBS-T, 100 μL of 2,2'-azinobis(3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt (ABTS, Cat No. 5110-0010, KPL, USA) solution was added and color development was confirmed. After homogenizing the dye in the 96-well plate, the absorbance at 405 nm (OD405) was measured using a microplate reader. The collagen production rate of citronellol was calculated by setting the OD405 of the control group as 100%.The OD405 of the control and citronellol were divided by the OD570 measured in 2-2 to calculate the collagen production rate per cell. The collagen production rate per cell for citronellol was calculated assuming that the collagen production rate per cell for the control group was 100%.
[0044] The results of 2-2 showed that there was no significant increase or decrease in fibroblast proliferation, confirming that citronellol had no cell-activating effect or toxicity. The results of 2-3 are shown in Table 3 as the collagen production rate by citronellol, with the collagen production rate of the control taken as 100%.
[0045] Table 3 confirms that the addition of citronellol significantly increased the collagen production rate per cell. These results demonstrate that citronellol increases the amount of collagen produced in fibroblasts. Taking the results of Example 1 into consideration, it is also suggested that the collagen-increasing effect of citronellol may be related to its inhibitory effect on collagen degradation by suppressing the expression of MMP-1.
[0046] From the above results, it is expected that citronellol, indole, farnesol, and amyl butyrate have a favorable effect on wrinkle improvement through the reduction of collagen-degrading enzymes and elastin-degrading enzymes or the increase of collagen by suppressing the expression of MMP-1 and NEP.
Claims
1. A wrinkle improving agent containing one or more active ingredients selected from citronellol, indole, farnesol, and amyl butyrate.
2. An MMP-1 expression inhibitor containing one or more active ingredients selected from citronellol, indole, farnesol, and amyl butyrate.
3. An NEP expression inhibitor containing one or more active ingredients selected from citronellol, indole, farnesol, and amyl butyrate.
4. A collagen decomposition inhibitor containing one or more active ingredients selected from citronellol, indole, farnesol, and amyl butyrate.
5. A collagen-increasing agent containing citronellol as an active ingredient.
Citation Information
Patent Citations
Skin cosmetics having functional flavor and method for producing the same
JP2022130050A
Collagen production promoter, MMP-2 inhibitor, cell growth promoter and internal agent
JP2022191664A
Wrinkle improving agent
JP2023001403A
Porous particle and cosmetic
JP2004262962A
Blend essential oil
JP2012017412A
